Skip to main content
Frank Balis, MD, Pediatric Hematology & Oncology, Philadelphia, PA, Children's Hospital of Philadelphia

FrankMiltonBalisMD

Pediatric Hematology & Oncology Philadelphia, PA

Professor, Pediatrics, Perelman School of Medicine

Dr. Balis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Balis' full profile

Already have an account?

  • Office

    3401 Civic Center Blvd
    Children's Hospital Of Philadelphia - Hem/Onc
    Philadelphia, PA 19104
    Phone+1 215-426-5414
  • Is this information wrong?

Education & Training

  • National Capital Consortium
    National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1982 - 1985
  • University of Washington
    University of WashingtonFellowship, Pediatric Hematology/Oncology, 1978 - 1981
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Pediatrics, 1975 - 1978
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1975

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2009 - 2024
  • MD State Medical License
    MD State Medical License 1982 - 2016
  • WA State Medical License
    WA State Medical License 1978 - 1982
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • GD2 as a circulating tumor biomarker (CTB) for neuroblastoma (NBL). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • A Pharmacologically-Based Approach to High Dose Methotrexate Administration to Investigate Nephrotoxicity and Acute Kidney Injury Biomarkers in Children and Adolescents with Newly Diagnosed Osteosarcoma
    A Pharmacologically-Based Approach to High Dose Methotrexate Administration to Investigate Nephrotoxicity and Acute Kidney Injury Biomarkers in Children and Adolescents with Newly Diagnosed OsteosarcomaMarch 7th, 2021

Grant Support

  • Fluorescent Pteridine Nucleoside AnalogsDivision Of Clinical Sciences - Nci2009
  • Anticancer Drug Development For Childhood CancersDivision Of Clinical Sciences - Nci2009
  • Clinical Pharmacology Of Anticancer DrugsDivision Of Basic Sciences - Nci2009
  • Clinical Pharmacology Of Anticancer DrugsNational Cancer Institute2008
  • Anticancer Drug Development For Childhood CancersNational Cancer Institute2008
  • Drug Development And Clinical Pharmacology Of Anticancer Drugs For Childhood CanNational Cancer Institute2007
  • Drug Development And Clinical Pharmacology Of AnticancerDivision Of Clinical Sciences - Nci2001–2006
  • Drug Development &Clinical Pharma. Of Anticancer DrugsDivision Of Clinical Sciences - Nci2004
  • Drug Development &Clinical Pharmacology Of Anticancer DDivision Of Clinical Sciences - Nci2000
  • Drug Development And Clinical Pharmacology Of Anticancer And Antiretroviral DrugsDivision Of Clinical Sciences - Nci1999
  • Clinical Pharmacology Of Anticancer And Antiretroviral DrugsDivision Of Clinical Sciences - Nci1996–1998

Professional Memberships

Hospital Affiliations